Buserelin vs Leuprolide — Peptide Comparison

At a Glance

Quickcomparison

Dose Range

Buserelin

200 mcg–1,500 mcg mcg

Leuprolide

3.75 mg–45 mg monthly or 3-month injections (depending on formulation)

Frequency

Once daily

Administration

Subcutaneous injection

Subcutaneous injection (daily)

Cycle Length

Ongoing/indefinite

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefitratings

Hormone Suppression

Cancer Management

Fertility Support

Endometriosis & Fibroid Relief

Hormone Control

Technical Data

Compoundspecifications

Molecular Formula

C60H86N16O13

Molecular Weight

1239.4 g/mol

Half-Life

2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)

Bioavailability

~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)

CAS Number

57773-65-6

C59H84N16O12

1209.4 g/mol

Approximately 2-6 hours (varies by route of administration)

~95% (subcutaneous injection)

74381-53-6

Protocols

Dosingtiers

starting

500 mcg

Every 8 hours (3 times daily)

First 7 days

The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].

standard

200 mcg

Ongoing maintenance

After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].

400 mcg (2 sprays per nostril)

3 times daily (1,200 mcg/day)

The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].

6.3 mg

Once every 2 months

Long-term

A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].

advanced

9.45 mg

Once every 3 months

A larger implant lasts about 3 months between placements [5].

1 mg

Ongoing

The original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].

7.5 mg

Every month

The 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].

22.5 mg

Every 3 months

The 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].

30-45 mg

Every 4-6 months

The longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].

Applications

Bestsuited for

Managing advanced prostate cancer

Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating endometriosis and reducing associated pain

Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Optimizing ovarian response during fertility treatments

Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing advanced or metastatic prostate cancer

Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Controlling severe endometriosis pain

Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating symptomatic uterine fibroids

Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying early puberty in children

Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Hot flashes (very common in men)

Decreased libido and erectile dysfunction

Injection site pain or swelling

Nausea

Fatigue

Mood changes or depression

Joint or muscle pain

Headaches

Dizziness

Thinning hair

Decreased bone density (osteoporosis with long-term use)

QT prolongation (rare but serious cardiac effect)

Tumor flare (temporary worsening of cancer symptoms in first weeks)

Severe allergic reactions

Spinal cord compression risk in men with metastatic disease

Serious

Severe allergic reaction

Research Status

Safety& evidence

FDA Status

FDA approved for other use

Safety Overview

Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.

Contraindications

xPregnancy or breastfeeding

xHypersensitivity to GnRH agonists

xCertain bone diseases when long-term use is planned

FDA approved for this use

Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient.

xPregnancy or breastfeeding (teratogenic)

xUndiagnosed vaginal bleeding

xActive bone metastases with spinal cord compression (increased fracture risk)

xAllergy to GnRH agonists or components

xSevere cardiovascular disease with QT prolongation risk

Decision Guide

Which isright for you?

Choose Buserelin if...

Managing advanced prostate cancer

Treating endometriosis and reducing associated pain

Optimizing ovarian response during fertility treatments

Choose Leuprolide if...

Managing advanced or metastatic prostate cancer

Controlling severe endometriosis pain

Treating symptomatic uterine fibroids

Delaying early puberty in children